Table 1.
Records including longitudinal data.
| T-cell markers | Age | Method | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author | Year | Outcome | Disease population | CD3 | CD4 | CD8 | CD4:CD8 | FoxP3 | Other | Years | Reporting metric | IHC/IF |
| Ancuta | 2014 | Relapse | Cancer | X | NR | IHC | ||||||
| Bethwaite | 1996 | Survival | Cancer | X | 43.7 | Mean | IHC | |||||
| Edwards | 1995 | Recurrence | Neoplasia | X | X | NR* | NR | IHC | ||||
| Enwere | 2017 | Survival | Cancer | X | 44 | Median | IHC | |||||
| Grochot | 2019 | Survival | Cancer | X | 44 | Median | IHC | |||||
| Hellberg | 2009 | Survival | Cancer | X | 59.7 | Mean | IHC | |||||
| Jordanova | 2008 | Survival | Cancer | X | CD8:FoxP3 | 48.5 | Mean | IF (CD8); IHC (FoxP3) | ||||
| Karageorgopoulou | 2017 | Survival | Cancer | X | X | 58 | Median | IHC | ||||
| Maluf | 2008 | Recurrence | CIN3 | X | X | CD68, CD45RO | 34.9 | Mean | IHC | |||
| Nedergaard | 2008 | Relapse | Cancer | X | X | X | X | CD57, CD68, CD45RO, CD45RA | 41.5 | Mean | IHC | |
| Origoni | 2013 | Recurrence | hgCIN | X | X | 37 | Mean | IHC | ||||
| Ovestad | 2011 | Regression | hgCIN | X | CD25, CD4:CD25, CD8:CD25 | NR | NR | IHC | ||||
| Punt | 2015 | Survival | Cancer | X | X | 40 | Median | IF | ||||
| Saglam | 2019 | Survival | Cancer | X | 47 | Mean | IHC | |||||
| Shah | 2011 | Survival | Cancer | X | X | X | X | 47 | Median | IHC | ||
| Syrjanen | 1985 | Regression/Persistence/Progression | Normal, CIN | X | X | X | X | 28.6 | Mean | IHC | ||
| Syrjanen | 1987 | Regression/Persistence/Progression | Normal CIN | X | X | X | X | 28.7 | Mean | IHC | ||
| Trimble | 2010 | Regression | hgCIN | X | NR | NR | IHC | |||||
| Vayrynen | 1985 | Regression/Persistence/Progression | CIN | X | X | X | X | 25-29 | Median | IHC | ||
| Woo | 2008 | Regression/Progression | CIN | X | X | X | CD56 | 20-30 | Range | IHC | ||
A total of 20 records were identified in the systematic review as containing longitudinal follow-up data on infiltrating T-cells makers and cervical disease outcome. The range of markers is indicated, as is the initial diagnosis (HPV infection, CIN/neoplasia, or cancer), what outcomes were followed, patient age, and method used.
CIN cervical intraepithelial neoplasia, FoxP3 forkhead/winged-helix transcription factor box P3, NR not reported, IHC immunohistochemistry, IF immunofluorescence.
*Cancer patients average 15 years older than CIN patients.